Armata Pharmaceuticals (ARMP) Convertible Debt (2023 - 2026)

Armata Pharmaceuticals has disclosed Convertible Debt across 4 years of filings, most recently posting $254.9 million for Q1 2026.

• Convertible Debt for Q1 2026 came in at $254.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $254.9 million (changed N/A YoY), and the FY2025 annual result was $153.9 million, up 367.7% from the prior year.
• Convertible Debt came in at $254.9 million for Q1 2026 at Armata Pharmaceuticals, up from $153.9 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $254.9 million in Q1 2026 to a low of $30.0 million in Q3 2024.
• The 4-year median for Convertible Debt is $41.3 million (2023), against an average of $80.0 million.
• Across the five-year window, Convertible Debt tumbled 43.89% in 2024 and soared 367.7% in 2025, its largest moves.
• Armata Pharmaceuticals' Convertible Debt stood at $58.6 million in 2023, then plunged by 43.89% to $32.9 million in 2024, then jumped by 367.7% to $153.9 million in 2025, then soared by 65.68% to $254.9 million in 2026.
• The last three Convertible Debt figures came in at $254.9 million (Q1 2026), $153.9 million (Q4 2025), and $30.0 million (Q3 2025), per Business Quant data.